LPRS2
MCID: LPR022
MIFTS: 26

Leprosy 2 (LPRS2)

Categories: Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leprosy 2

MalaCards integrated aliases for Leprosy 2:

Name: Leprosy 2 57
Leprosy, Susceptibility to, 2 57 28 5 71
Leprosy, Type 2 38
Leprosy 71
Lprs2 57

Classifications:



External Ids:

OMIM® 57 607572
UMLS 71 C0023343 C1843632

Summaries for Leprosy 2

MalaCards based summary: Leprosy 2, also known as leprosy, susceptibility to, 2, is related to leprosy 3 and oto-palatal-digital syndrome. An important gene associated with Leprosy 2 is PRKN (Parkin RBR E3 Ubiquitin Protein Ligase). The drugs Levoleucovorin and Folic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and neutrophil.

More information from OMIM: 607572

Related Diseases for Leprosy 2

Diseases in the Leprosy 3 family:

Leprosy 2 Leprosy 1
Leprosy 4 Leprosy 5
Leprosy 6

Diseases related to Leprosy 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leprosy 3 10.4
2 oto-palatal-digital syndrome 10.0
3 lepromatous leprosy 9.9
4 autoimmune disease 9.9
5 neutropenia 9.9
6 chromoblastomycosis 9.9
7 mucormycosis 9.9
8 tuberculoid leprosy 9.8

Graphical network of the top 20 diseases related to Leprosy 2:



Diseases related to Leprosy 2

Symptoms & Phenotypes for Leprosy 2

Clinical features from OMIM®:

607572 (Updated 08-Dec-2022)

Drugs & Therapeutics for Leprosy 2

Drugs for Leprosy 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
3 Vitamins Phase 4
4 Anti-Bacterial Agents Phase 4
5 Anti-Infective Agents Phase 4
6 Folic Acid Antagonists Phase 4
7 Folate Phase 4
8 Vitamin B9 Phase 4
9 Antiprotozoal Agents Phase 4
10 Antiparasitic Agents Phase 4
11 Vitamin B Complex Phase 4
12 Antimalarials Phase 4
13
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
14
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
15
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 4894 5755
16
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5 1875
17
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 4159 6741
18
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
19
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
20
Amitriptyline Approved Phase 3 50-48-6 2160
21
Tramadol Approved, Investigational Phase 3 27203-92-5 33741 5523
22
Bedaquiline Approved Phase 3 843663-66-1 5388906
23
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7 4897
24 Immunosuppressive Agents Phase 2, Phase 3
25 Hormones Phase 2, Phase 3
26 Hormone Antagonists Phase 2, Phase 3
27 Antirheumatic Agents Phase 2, Phase 3
28 Antineoplastic Agents, Hormonal Phase 2, Phase 3
29 Calcineurin Inhibitors Phase 2, Phase 3
30 Cyclosporins Phase 2, Phase 3
31 Antifungal Agents Phase 2, Phase 3
32 glucocorticoids Phase 2, Phase 3
33
Methylprednisolone Acetate Phase 2, Phase 3 584547
34 Immunologic Factors Phase 2, Phase 3
35 Analgesics Phase 3
36 Neurotransmitter Agents Phase 3
37 Adrenergic Agents Phase 3
38 Psychotropic Drugs Phase 3
39 Antidepressive Agents, Tricyclic Phase 3
40 Antidepressive Agents Phase 3
41 Analgesics, Opioid Phase 3
42 Analgesics, Non-Narcotic Phase 3
43 Narcotics Phase 3
44 Antitubercular Agents Phase 3
45 Antibiotics, Antitubercular Phase 3
46 Immunoglobulin M Phase 3
47
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
48
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
49
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
50 CC-11050 Investigational Phase 2 340019-69-4

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
4 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
5 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
6 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Active, not recruiting NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
7 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Active, not recruiting NCT03662022 Phase 3 Rifampicin
8 Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 3 Study Not yet recruiting NCT05597280 Phase 3 BE-PEP Bedaquiline;SDR-PEP Rifampicin;BE-PEP Rifampicin
9 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
10 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
11 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
12 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
13 Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 2 Study Recruiting NCT05406479 Phase 2 BE-PEP (Bedaquiline);SDR-PEP;BE-PEP (Rifampicine)
14 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
15 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Active, not recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
16 Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in Indonesia Not yet recruiting NCT05243654 Phase 2 Metformin;Placebo
17 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
18 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
19 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
20 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
21 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
22 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
23 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
24 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
25 Observation of Microcirculation Impairment in Patients With Lepromatous Leprosy Using Orthogonal Polarization Spectral (OPS) Imaging and Laser Doppler Iontophoresis Completed NCT02085317 acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis
26 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717
27 Improved Understanding of Ongoing Transmission of Leprosy in the Comoros, a Region Hyperendemic for the Disease. Completed NCT03526718
28 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
29 Educational Virtual Objects (The Virtual Human Project) Assessment Inserted in Learning Based on Team (Team-based Learning) in Leprosy Education on Undergraduate Medical Setting Completed NCT02484469
30 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
31 Modified Tarsorrhaphy vs Gold Weight Implant Technique for Paralytic Lagophthalmos Treatment in Leprosy Patients: a Randomized Clinical Trial Completed NCT04944498
32 The Evaluation of Treatment of Leprosy Wounds With Traditional Chinese Herbal Medicine Complex "Jingchuang Ointment" Recruiting NCT05047809
33 Epidemiology of Leprosy in French Guiana Recruiting NCT05031091
34 A Clinical Study on the Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients in Taiwan Recruiting NCT05091216
35 Clofazamine in the Long Term Treatment of Leprosy, Phase III No longer available NCT00852345 clofazamine
36 CD8 Reactivity to Microorganisms in Blood and Breast Milk Terminated NCT03084614
37 Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer. Terminated NCT01751503

Search NIH Clinical Center for Leprosy 2

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Genetic Tests for Leprosy 2

Genetic tests related to Leprosy 2:

# Genetic test Affiliating Genes
1 Leprosy, Susceptibility to, 2 28

Anatomical Context for Leprosy 2

Organs/tissues related to Leprosy 2:

MalaCards : Skin, Breast, Neutrophil

Publications for Leprosy 2

Articles related to Leprosy 2:

(show top 50) (show all 53)
# Title Authors PMID Year
1
Linkage disequilibrium pattern and age-at-diagnosis are critical for replicating genetic associations across ethnic groups in leprosy. 57
23052943 2013
2
Association study of major risk single nucleotide polymorphisms in the common regulatory region of PARK2 and PACRG genes with leprosy in an Indian population. 57
16391553 2006
3
Susceptibility to leprosy is associated with PARK2 and PACRG. 57
14737177 2004
4
Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. 57
12577057 2003
5
A major susceptibility locus for leprosy in India maps to chromosome 10p13. 57
11279529 2001
6
Genomic control for association studies. 57
11315092 1999
7
Are the neglected tropical diseases under control in the tri-border region between Brazil, Argentina, and Paraguay? 62
35404862 2022
8
A comparison of three types of targeted, community-based methods aimed at promoting early detection of new leprosy cases in rural parts of three endemic states in India. 62
34905570 2021
9
Neutrophil extracellular traps contribute to the pathogenesis of leprosy type 2 reactions. 62
31504035 2019
10
Study of S100 Immunostaining in Demonstrating Neural Granulomas in Paucibacillary Leprosy. 62
29937557 2018
11
Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum. 62
27556927 2016
12
Profile of Rheumatological Manifestations in Leprosy in a Tertiary Care Hospital from Himachal Pradesh. 62
29741821 2016
13
Neuropathy in elderly: lessons learnt from nerve biopsy. 62
25362502 2015
14
Lucio Leprosy with Lucio's phenomenon, digital gangrene and anticardiolipin antibodies. 62
25509720 2014
15
Clinical use and control of the dispensing of thalidomide in Brasilia-Federal District, Brazil, from 2001 to 2012. 62
24196904 2013
16
Delusional infestation: a clinical profile. 62
23466108 2013
17
Patterns of migration and risks associated with leprosy among migrants in Maranhão, Brazil. 62
24040433 2013
18
Mucormycosis and chromoblastomycosis occurring in a patient with leprosy type 2 reaction under prolonged corticosteroid and thalidomide therapy. 62
23044573 2012
19
Genetic and immunological evidence implicates interleukin 6 as a susceptibility gene for leprosy type 2 reaction. 62
22459738 2012
20
Azathioprine as a steroid sparing agent in leprosy type 2 reactions: report of nine cases. 62
22125939 2011
21
[The current challenge of imported leprosy in Spain: a study of 7 cases]. 62
21334586 2011
22
[Epidemiological profile of leprosy in a Brazilian municipality between 2000 and 2006]. 62
20305971 2010
23
Leprosy. 62
19454067 2007
24
[Late-occurring cutaneous vasculitis after successful treatment of diffuse lepromatous leprosy: Lucio's phenomenon]. 62
17506277 2007
25
Increased prevalence of human T cell lymphotropic virus type 1 in patients attending a Brazilian dermatology clinic. 62
17622792 2007
26
Study of patients presenting with symptoms of peripheral neuropathy and thickened greater auricular nerve. 62
16340253 2003
27
Male-female (sex) differences in leprosy patients in south eastern Nigeria: females present late for diagnosis and treatment and have higher rates of deformity. 62
12449892 2002
28
Spectrum of dermatopathologic lesions associated with HIV/AIDS in India. 62
12785169 2002
29
Ocular manifestations of leprosy in a noninstitutionalized community in the United States. 62
8185519 1994
30
Denatured muscle grafts for nerve repair in an experimental model of nerve damage in leprosy. 2. Recovery of peripheral peptide-containing nerves assessed by quantitative immunohistochemical study. 62
7514642 1994
31
Intracardiac autonomic ganglion cells in leprosy and dilated cardiomyopathy. 62
8365740 1993
32
[Cutaneous neoplasms during leprosy: 2 case reports]. 62
1293912 1992
33
A study of morbidity pattern among prostitutes attending a municipal clinic in Pune. 62
2789264 1989
34
[Study on prevention of leprosy. 2. Chemo-prophylaxis trial for leprosy household contact children]. 62
3842969 1985
35
Leprosy. XII. T-cell subsets in lepromatous leprosy. 62
6983504 1982
36
Phagocytosis in leprosy. 2. Production of superoxide by circulating blood leukocytes from lepromatous patients. 62
215566 1978
37
Persistence of Australia antigen in leprosy--a frustrating puzzle in immunology. 62
651319 1978
38
The role of protein malnutrition in the pathogenesis of ulcerative "Lazarine" leprosy. 62
824211 1976
39
The histopathology of lepromatous leprosy in the nose. 62
1099180 1975
40
Acid mucopolysaccharide metabolism in leprosy. 2. Subcellular localization of hyaluronic acid and beta-glucuronidase in leprous infiltrates suggestive of a host-Mycobacterium leprae metabolic relationship. 62
4282081 1974
41
Experimental murine leprosy. 2. Further evidence for varying susceptibility of outbred mice and evaluation of the response of 5 inbred mouse strains to infection with Mycobacterium lepraemurium. 62
4604462 1974
42
Immunologic studies on leprosy. 2. Antigenic studies of Mycobacterium leprae. 62
4131110 1973
43
The control and management of leprosy. 2. 62
4496656 1973
44
Lipids in leprosy. 2. Histochemistry of lipids in human leprosy. 62
4102020 1970
45
Leprosy. 2. 62
5434944 1970
46
Nerves in the arm in leprosy. 2. Pathology, pathogenesis and clinical correlations. 62
4098603 1970
47
[Consideration and discussion of the pathogenesis of leprosy, with special reference to the influence of specific histological changes in the reticuloendothelial system on the progress of and recovery from leprosy. 2]. 62
5686369 1968
48
Studies on sulfone resistance in leprosy. 2. Treatment with a riminophenazine derivative (B.663). 62
6006070 1966
49
The facial nerve in leprosy. 2. Pathology, pathogenesis, electromyography and clinical correlations. 62
5950064 1966
50
Epidemiology of disability in leprosy. 2. Factors associated with low disability. 62
5950068 1966

Variations for Leprosy 2

ClinVar genetic disease variations for Leprosy 2:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PRKN NM_004562.3(PRKN):c.823C>T (p.Arg275Trp) SNV Pathogenic
7050 rs34424986 GRCh37: 6:162206852-162206852
GRCh38: 6:161785820-161785820

Expression for Leprosy 2

Search GEO for disease gene expression data for Leprosy 2.

Pathways for Leprosy 2

GO Terms for Leprosy 2

Sources for Leprosy 2

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....